Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira (adalimumab)

20.09.2023 - REYKJAVIK, Iceland, Sept. 20, 2023 (GLOBE NEWSWIRE) - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the U.S. ... Seite 1

Related Keywords

Canada ,Saudi Arabia ,United Kingdom ,Liechtenstein ,Egypt ,Switzerland ,Iceland ,Australia ,Norway ,Lichtenstein ,Robert Wessman ,European Union ,Alvotech Chart ,Lvotech Kurs ,Lvotech Aktie ,